Neurocrine Biosciences Inc (NBIX)
140.71
+0.88
(+0.63%)
USD |
NASDAQ |
May 03, 16:00
140.77
+0.06
(+0.04%)
After-Hours: 20:00
Neurocrine Biosciences Free Cash Flow (Quarterly): 119.10M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 119.10M |
| December 31, 2023 | 118.10M |
| September 30, 2023 | 204.40M |
| June 30, 2023 | 172.80M |
| March 31, 2023 | -133.70M |
| December 31, 2022 | 141.20M |
| September 30, 2022 | 100.50M |
| June 30, 2022 | 129.30M |
| March 31, 2022 | -48.10M |
| December 31, 2021 | -4.70M |
| September 30, 2021 | 56.10M |
| June 30, 2021 | 98.90M |
| March 31, 2021 | 82.80M |
| December 31, 2020 | 90.00M |
| September 30, 2020 | -20.80M |
| June 30, 2020 | 114.20M |
| March 31, 2020 | 34.20M |
| December 31, 2019 | 94.70M |
| September 30, 2019 | 94.30M |
| June 30, 2019 | 59.70M |
| March 31, 2019 | -116.40M |
| December 31, 2018 | 44.49M |
| September 30, 2018 | 56.56M |
| June 30, 2018 | 15.84M |
| March 31, 2018 | -40.29M |
| Date | Value |
|---|---|
| December 31, 2017 | 38.20M |
| September 30, 2017 | -12.11M |
| June 30, 2017 | -48.64M |
| March 31, 2017 | -78.72M |
| December 31, 2016 | -31.97M |
| September 30, 2016 | -31.79M |
| June 30, 2016 | -16.58M |
| March 31, 2016 | -29.95M |
| December 31, 2015 | -16.03M |
| September 30, 2015 | -18.89M |
| June 30, 2015 | 13.45M |
| March 31, 2015 | -18.46M |
| December 31, 2014 | -15.75M |
| September 30, 2014 | -12.37M |
| June 30, 2014 | -10.61M |
| March 31, 2014 | -10.02M |
| December 31, 2013 | -11.07M |
| September 30, 2013 | -10.81M |
| June 30, 2013 | -10.12M |
| March 31, 2013 | 1.853M |
| December 31, 2012 | -8.951M |
| September 30, 2012 | -8.61M |
| June 30, 2012 | -7.096M |
| March 31, 2012 | -11.61M |
| December 31, 2011 | 10.98M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-133.70M
Minimum
Mar 2023
204.40M
Maximum
Sep 2023
75.15M
Average
94.50M
Median
Free Cash Flow (Quarterly) Benchmarks
| Globus Medical Inc | 81.79M |
| Inspire Medical Systems Inc | 9.234M |
| AIM ImmunoTech Inc | -9.956M |
| Protalix BioTherapeutics Inc | 3.345M |
| Armata Pharmaceuticals Inc | -10.51M |